Palisade Bio Past Earnings Performance
Past criteria checks 0/6
Palisade Bio's earnings have been declining at an average annual rate of -3.9%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 52.7% per year.
Key information
-3.9%
Earnings growth rate
2.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -52.7% |
| Return on equity | -108.7% |
| Net Margin | -4,926.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Palisade Bio: Guarding Intestinal Integrity
Nov 07Revenue & Expenses BreakdownBeta
How Palisade Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -12 | 6 | 7 |
| 30 Sep 23 | 0 | -13 | 6 | 8 |
| 30 Jun 23 | 0 | -14 | 7 | 8 |
| 31 Mar 23 | 0 | -13 | 7 | 7 |
| 31 Dec 22 | 0 | -15 | 9 | 7 |
| 30 Sep 22 | 0 | -9 | 10 | 5 |
| 30 Jun 22 | 0 | 0 | 11 | 4 |
| 31 Mar 22 | 0 | -27 | 11 | 3 |
| 31 Dec 21 | 0 | -27 | 9 | 2 |
| 30 Sep 21 | 0 | -32 | 9 | 2 |
| 30 Jun 21 | 0 | -39 | 8 | 2 |
| 31 Mar 21 | 0 | -12 | 6 | 3 |
| 31 Dec 20 | 0 | -10 | 6 | 3 |
| 30 Sep 20 | 0 | -9 | 6 | 3 |
| 31 Dec 19 | 0 | -10 | 7 | 3 |
| 31 Dec 18 | 1 | -4 | 4 | 1 |
Quality Earnings: PALI is currently unprofitable.
Growing Profit Margin: PALI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PALI is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.
Accelerating Growth: Unable to compare PALI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PALI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: PALI has a negative Return on Equity (-108.72%), as it is currently unprofitable.